A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer

American Journal of Medicine

Volumn 108, Issue 4, 2000, Pages 282-289

  Winston, Drew J ^a,d   Hathorn, James W ^b   Schuster, Mindy G ^c   Schiller, Gary J ^a   Territo, Mary C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CAUSE OF DEATH; FEMALE; FEVER; FLUCONAZOLE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYCOSES; NEOPLASMS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 0033972985     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00457-X     Document Type: Article

References (36)

1. Anaissie EJ. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis. 1992; 14(suppl 1):S43-S53.
2. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am. 1996;10:365-400.
3. Ribaud P. Fungal infections and the cancer patient. Eur J Cancer. 1997;33(suppl 4):S50-S54.
4. Rinaldi MG. Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis. 1991;13:493-495.
5. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. EurJ Clin Microbiol Infect Dis. 1992;11:99-109.
6. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101-111.
7. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86:668-672.
8. Sugar AM. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use. Arch Intern Med. 1990;150:2258-2264.
9. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. NEJM. 1993;328:1323-1332.
10. Gallis HA, Drew R, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12:308-329.
11. Como HA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. NEJM. 1994;330:263-272.
12. Grant SM, Clinold SP. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs. 1990;39:877-916.
13. Walsh TJ, Lee J, Aoki S, et al. Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis. 1990;12(suppl 3):S307-S317.
14. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. NEJM. 1992;326:845-851.
15. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized, placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118:495-503.
16. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med. 1996;101:170-176.
17. Anaissie EJ, Parouiche R, Abi-Said D. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996;23:964-972.
18. Patterson TF, Miniter P, Andriole VT. Efficacy of fluconazole in experimental aspergillosis. Rev Infect Dis. 1990;12(suppl 3):S281-S285.
19. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. NEJM 1994;331:1325-1330.
20. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990; 12(suppl 2):S318-S326.
21. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley and Sons; 1981.
22. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomized clinical trial. Eur J Cancer. 1996;32A: 814-820.
23. Marie JP, Lapierre V, Pico J, et al. Randomized multicentre trial of intravenous fluconazole versus intravenous amphotericin B in neutropenic febrile patients. Cah Oncol. 1993;2:171-173.
24. Silling G, Fegeler W, Roos N, et al. Fluconazole versus amphotericin B-5-flucytosine for the treatment of febrile neutropenia. Ann Hematol. 1995;70(suppl 2):A101.
25. Malik IA, Moid I, Aziz Z, et al.. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med. 1998; 6:478-483.
26. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711-718.
27. White MH, Bowden RA, Sandler ES, et al. Randomized, doubleblind clinical trial of amphotericin B 7olloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27:296-302.
28. Rowe JM. Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clin Infect Dis. 1998;26:1290-1294.
29. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997;89:2233-2258.
30. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1997;19:801-808.
31. Meis JF, Donnelly JP, Hoogkamp-Korstanje J, De Pauw BE. Aspergillus fumigatus pneumonia in neutropenic patients during therapy with fluconazole for infection due to Candida species. Clin Infect Dis. 1993;16:734-735.
32. Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993;37:1847-1849.
33. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. NEJM. 1991;325:1274-1277.
34. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplant. A prospective, randomized, double-blind study. J Infect Dis. 1995; 171:1545-1552.
35. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. NEJM. 1999;340:764-771.
36. 1998 Drug Topics Red Book. Montvale, NJ: Medical Economics; 1998.